Inhibition of T-Cell Activation by Retinal Pigment Epithelial Cells Derived From Induced Pluripotent Stem Cells
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
PURPOSE: The purpose of this study was to determine whether human retinal pigment epithelial (RPE) cells from induced pluripotent stem (iPS) cells could inhibit T-cell activation in vitro. METHODS: Cultured iPS-derived RPE (iPS-RPE) cells were established from fresh skin tissues or dental pulp cells obtained from healthy donors or a retinal patient after informed consent was obtained. To confirm expression of the specific markers on iPS and iPS-RPE cells, immunohistochemistry, quantitative RT-PCR (qRT-PCR), and flow cytometry were performed. Target T cells were obtained from peripheral blood mononuclear cells of healthy donors. Target T cells were assessed for proliferation by incorporation of bromodeoxyuridine or carboxyfluorescein succinimidyl ester for production of cytokines such as IFN-γ. Expression of TGFβ and other candidate molecules by iPS-RPE cells was evaluated with flow cytometry, ELISA, multiplex cytokine array, immunohistochemistry, and qRT-PCR. RESULTS: The RPE cells we established from iPS cells had many characteristics of mature RPE cells but no characteristics of pluripotent stem cells. Cultured iPS-RPE cells inhibited cell proliferation and production of IFN-γ by activated CD4(+) T cells. In some bystander T cells, iPS-derived RPE cells induced CD25(+)Foxp3(+) regulatory T cells in vitro. Induced pluripotent stem-RPE cells constitutively expressed TGFβ and suppressed activation of T cells via soluble TGFβ, because TGFβ-downregulated iPS-RPE cells did not inhibit this T-cell activation. CONCLUSIONS: Cultured iPS-derived retinal cells fully suppress T-cell activation. Transplantation of iPS-RPE cells into the eye might be a therapy for retinal disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
Ocular immune privilege: therapeutic opportunities from an experiment of nature
Streilein, J. W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1224 · Cited by 807
Peyman, G. A., Blinder, K. J., Paris, C. L., Alturki, W., Nelson, N. C., & Desai, U. (1991) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-19910201-12 · Cited by 227
Immune privilege in the anterior chamber of the eye
Niederkorn, J. Y. (2002) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v22.i1.20 · Cited by 147
ALLOGENIC FETAL RETINAL PIGMENT EPITHELIAL CELL TRANSPLANT IN A PATIENT WITH GEOGRAPHIC ATROPY
WEISZ, J. M., HUMAYUN, M. S., JUAN, E. D., CERRO, M. D., SUNNESS, J. S., DAGNELIE, G., SOYLU, M., RIZZO, L., & NUSSENBLATT, R. B. (1999) · Retina · doi:10.1097/00006982-199919060-00011 · Cited by 5
Cited by
Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608368 · Cited by 1,509
Self-citationHLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration
Sugita, S., Mandai, M., Hirami, Y., Takagi, S., Maeda, T., Fujihara, M., Matsuzaki, M., Yamamoto, M., Iseki, K., Hayashi, N., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072217 · Cited by 190
“However, RPE cells including those established from iPS/ES cells exhibit immunosuppressive properties [14,15] with the eye also shown to be an immune privileged site [16,17].”
BackgroundSelf-citationSugita, S., Iwasaki, Y., Makabe, K., Kamao, H., Mandai, M., Shiina, T., Ogasawara, K., Hirami, Y., Kurimoto, Y., & Takahashi, M. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.08.010 · Cited by 156
“Signal inhibitors Y-27632 (10 mM, Wako), SB431542 (5 mM, Sigma), and CKI-7 (3 mM, Sigma) were added to the GMEM (Kamao et al., 2014; Sugita et al., 2015).”
MethodInfluentialSelf-citationImmunological aspects of RPE cell transplantation
Sugita, S., Mandai, M., Kamao, H., & Takahashi, M. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100950 · Cited by 77
“In addition, RPE cells secrete the IFN-γ-related chemokines CXCL9 (MIG), CXCL10 (IP-10), CXCL11 (I-TAC) (Juel et al., 2012), IL-6 (Sugita et al., 2015), and CCL2 (monocyte chemoattractant protein-1: MCP-1) (Juel et al., 2012; Sugita et al., 2015) and express the positive co-stimulatory molecule B7–H3 (CD276) (Sugita e…”
BackgroundMethodInfluentialSelf-citationReduction of lipid accumulation rescues Bietti's crystalline dystrophy phenotypes
Hata, M., Ikeda, H. O., Iwai, S., Iida, Y., Gotoh, N., Asaka, I., Ikeda, K., Isobe, Y., Hori, A., Nakagawa, S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717338115 · Cited by 70
“Thereafter, we induced BCD and NOR iPSCs to differentiate toward RPE cells (14).”
MethodStem cell-based therapy for diseases of the retinal pigment epithelium: from bench to bedside
Sachdeva, M. M., & Eliott, D. (2016) · Seminars in Ophthalmology · doi:10.3109/08820538.2015.1115253 · Cited by 28
Metadata
- Authors
- Sugita, S., Kamao, H., Iwasaki, Y., Okamoto, S., Hashiguchi, T., Iseki, K., Hayashi, N., Mandai, M., & Takahashi, M.
- Venue
- Investigative Ophthalmology & Visual Science
- Published
- 2015-01-20
- Volume
- 56
- Issue
- 2
- Pages
- 1051-1062
- ISSN
- 0146-0404 (ISSN-L)
- OpenAlex
- W2005477099
- Cited by
- 71
- References
- 5
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.